Barclays PLC Sells 188,297 Shares of The Cooper Companies, Inc. $COO

Barclays PLC decreased its holdings in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 28.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 471,430 shares of the medical device company’s stock after selling 188,297 shares during the period. Barclays PLC owned about 0.24% of Cooper Companies worth $32,321,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Sustainable Growth Advisers LP bought a new stake in Cooper Companies during the second quarter valued at about $240,881,000. Ameriprise Financial Inc. lifted its position in shares of Cooper Companies by 98.8% during the 2nd quarter. Ameriprise Financial Inc. now owns 3,388,413 shares of the medical device company’s stock valued at $241,120,000 after buying an additional 1,683,561 shares in the last quarter. Franklin Resources Inc. grew its stake in shares of Cooper Companies by 7,723.3% during the 2nd quarter. Franklin Resources Inc. now owns 1,569,512 shares of the medical device company’s stock valued at $111,686,000 after acquiring an additional 1,549,450 shares during the period. Massachusetts Financial Services Co. MA increased its holdings in Cooper Companies by 96.9% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,099,750 shares of the medical device company’s stock worth $212,519,000 after acquiring an additional 1,525,693 shares in the last quarter. Finally, Findlay Park Partners LLP raised its stake in Cooper Companies by 312.5% during the 2nd quarter. Findlay Park Partners LLP now owns 1,815,900 shares of the medical device company’s stock worth $129,219,000 after acquiring an additional 1,375,657 shares during the period. 24.39% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Cooper Companies

In other news, Director Maria Rivas acquired 1,000 shares of Cooper Companies stock in a transaction on Thursday, December 18th. The shares were bought at an average cost of $82.13 per share, for a total transaction of $82,130.00. Following the acquisition, the director directly owned 11,141 shares of the company’s stock, valued at $915,010.33. This trade represents a 9.86% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Holly R. Sheffield acquired 1,230 shares of the firm’s stock in a transaction that occurred on Tuesday, December 16th. The stock was purchased at an average price of $80.75 per share, with a total value of $99,322.50. Following the completion of the acquisition, the insider directly owned 39,052 shares of the company’s stock, valued at $3,153,449. This represents a 3.25% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders bought 16,014 shares of company stock valued at $1,304,416. 2.08% of the stock is owned by corporate insiders.

Key Cooper Companies News

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Insiders bought shares and management continues aggressive buybacks, signaling confidence in the company’s long‑term outlook and supporting a rebound thesis; Q1 results beat consensus and buybacks help earnings-per-share support. CooperCompanies Insiders Buy as Rebound Setup Forms
• Positive Sentiment: An analyst raised Cooper’s price target to $103, indicating there is still perceived upside from current levels among some research houses. Cooper Companies (NASDAQ:COO) Price Target Raised to $103.00
• Neutral Sentiment: Analyst coverage pieces (Zacks) profile COO as a long‑term value play and highlight the importance of international revenue trends—useful context but not an immediate catalyst. Why The Cooper Companies (COO) is a Top Value Stock for the Long-Term
• Neutral Sentiment: Another Zacks write-up urges monitoring of international revenue patterns—this is informational for forecasting revisions but not an immediate market mover. Investing in The Cooper Companies (COO)? Don’t Miss Assessing Its International Revenue Trends
• Negative Sentiment: Citigroup cut its price target to $87, signaling at least one major shop has become more cautious on near‑term upside — this likely adds to short‑term selling pressure and contributes to today’s decline. Citigroup Cuts Cooper Companies (NASDAQ:COO) Price Target to $87.00

Cooper Companies Price Performance

COO stock opened at $74.41 on Wednesday. The company has a current ratio of 1.34, a quick ratio of 0.79 and a debt-to-equity ratio of 0.22. The Cooper Companies, Inc. has a 12 month low of $61.78 and a 12 month high of $89.83. The stock has a market cap of $14.52 billion, a PE ratio of 36.84, a P/E/G ratio of 1.95 and a beta of 1.02. The company has a 50-day moving average price of $81.82 and a 200 day moving average price of $76.01.

Cooper Companies (NASDAQ:COO) last released its earnings results on Thursday, March 5th. The medical device company reported $1.10 EPS for the quarter, beating analysts’ consensus estimates of $1.03 by $0.07. Cooper Companies had a return on equity of 10.34% and a net margin of 9.67%.The firm had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1.02 billion. During the same quarter in the prior year, the firm posted $0.92 earnings per share. The company’s quarterly revenue was up 6.2% on a year-over-year basis. Cooper Companies has set its Q2 2026 guidance at 4.580-4.660 EPS. Equities research analysts anticipate that The Cooper Companies, Inc. will post 3.98 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts recently issued reports on COO shares. William Blair upgraded Cooper Companies to a “strong-buy” rating in a research report on Friday, January 30th. Morgan Stanley lifted their price objective on shares of Cooper Companies from $76.00 to $83.00 and gave the company an “equal weight” rating in a research report on Monday, December 8th. Citigroup dropped their target price on shares of Cooper Companies from $88.00 to $87.00 and set a “neutral” rating for the company in a research report on Friday, March 6th. Stifel Nicolaus set a $95.00 price target on shares of Cooper Companies and gave the stock a “buy” rating in a research note on Friday, December 5th. Finally, Weiss Ratings raised shares of Cooper Companies from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, January 12th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Cooper Companies currently has a consensus rating of “Moderate Buy” and a consensus price target of $90.79.

About Cooper Companies

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.